(Q44058238)

English

Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 November 2017

Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha (English)

1 reference

Europe PubMed Central

29 November 2017

author name string

U Keilholz

1

1 reference

Europe PubMed Central

29 November 2017

P Martus

2

1 reference

Europe PubMed Central

29 November 2017

C J A Punt

3

1 reference

Europe PubMed Central

29 November 2017

W Kruit

4

1 reference

Europe PubMed Central

29 November 2017

G Mooser

5

1 reference

Europe PubMed Central

29 November 2017

D Schadendorf

6

1 reference

Europe PubMed Central

29 November 2017

D Liénard

7

1 reference

Europe PubMed Central

29 November 2017

R Dummer

8

1 reference

Europe PubMed Central

29 November 2017

J Koller

9

1 reference

Europe PubMed Central

29 November 2017

C Voit

10

1 reference

Europe PubMed Central

29 November 2017

A M M Eggermont

11

1 reference

Europe PubMed Central

29 November 2017

publication date

1 July 2002

1 reference

Europe PubMed Central

29 November 2017

European Journal of Cancer

1 reference

Europe PubMed Central

29 November 2017

38

1 reference

Europe PubMed Central

29 November 2017

1501-1511

1 reference

Europe PubMed Central

29 November 2017

11

1 reference

Europe PubMed Central

29 November 2017

Combination chemotherapy in metastatic malignant melanoma.A randomized study of three DTIC-containing combinations

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination chemotherapy plus BCG in the treatment of disseminated malignant melanoma: a Southwest Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Gr

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Desmoids in familial adenomatous polyposis are monoclonal proliferations

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III)

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon-alpha and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential chemoimmunotherapy in the treatment of metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of survival by tumor response.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Is serum cholesterol associated with progression of diabetic retinopathy or macular edema in persons with younger-onset diabetes of long duration?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunotherapy of metastatic melanoma with interferon-alpha and interleukin-2: pattern of progression in responders and patients with stable disease with or without resection of residual lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900123-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0959-8049(02)00123-5

1 reference

Europe PubMed Central

29 November 2017

1 reference

Europe PubMed Central

29 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44058238&oldid=2106111289"